AstraZeneca: Leweichu has been approved in China for the prevention of respiratory syncytial virus infection in infants
海角七号
发表于 2024-1-2 16:19:34
276
0
0
AstraZeneca: Leweichu has been approved in China for the prevention of respiratory syncytial virus infection in infants. AstraZeneca and Sanofi jointly announced on January 2 that the long-acting monoclonal antibody Nirsevimab/Nissevir monoclonal antibody has been officially approved for marketing by the China National Medical Products Administration to prevent lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in newborns and infants. This medication is suitable for newborns and infants who are about to enter or are born during the first RSV infection season. Nisevizumab is expected to be launched in China during the RSV infection season of 2024-2025.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- AbbVie Dual Anti Cancer New Drug Declares for Market in China
- A sharp drop of 87%! Maserati will only sell over 30 units in China in September! Has the 'Sports Car Queen' fallen from grace?
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Sanofi's BTK inhibitor is declared for market in China